Nate Crossett

Stock Analyst at Exane BNP Paribas

(1.95)
# 3,008
Out of 4,876 analysts
38
Total ratings
50%
Success rate
0.83%
Average return

Stocks Rated by Nate Crossett

Medical Properties Trust
Mar 12, 2025
Upgrades: Outperform
Price Target: $5$9
Current: $4.44
Upside: +102.93%
Omega Healthcare Investors
Feb 8, 2024
Upgrades: Neutral
Price Target: $30
Current: $36.60
Upside: -18.03%
Agree Realty
Dec 13, 2023
Downgrades: Neutral
Price Target: $64
Current: $72.46
Upside: -11.68%
NETSTREIT
Dec 13, 2023
Downgrades: Neutral
Price Target: $17
Current: $16.74
Upside: +1.55%
Realty Income
Dec 13, 2023
Upgrades: Outperform
Price Target: $63
Current: $57.15
Upside: +10.24%
Alexandria Real Estate Equities
Oct 11, 2023
Initiates: Neutral
Price Target: $108
Current: $73.80
Upside: +46.34%
Ventas
Oct 11, 2023
Initiates: Outperform
Price Target: n/a
Current: $63.03
Upside: -
Digital Realty Trust
Jul 28, 2023
Upgrades: Outperform
Price Target: $138
Current: $170.97
Upside: -19.28%
Prologis
Jul 20, 2023
Upgrades: Outperform
Price Target: $141
Current: $105.95
Upside: +33.08%
Gaming and Leisure Properties
Jun 14, 2023
Initiates: Outperform
Price Target: $63
Current: $46.33
Upside: +35.98%
Initiates: Underperform
Price Target: $42
Current: $42.91
Upside: -2.12%
Initiates: Outperform
Price Target: $41
Current: $32.27
Upside: +27.05%
Initiates: Outperform
Price Target: $29
Current: $32.10
Upside: -9.64%
Initiates: Underperform
Price Target: $74
Current: $62.98
Upside: +17.50%
Initiates: Outperform
Price Target: n/a
Current: $15.80
Upside: -
Initiates: Underperform
Price Target: $9.6
Current: $7.48
Upside: +28.34%
Initiates: Outperform
Price Target: $66
Current: $101.58
Upside: -35.03%
Initiates: Outperform
Price Target: $38
Current: $16.87
Upside: +125.32%
Initiates: Outperform
Price Target: $886
Current: $783.50
Upside: +13.08%
Downgrades: Hold
Price Target: $31$30
Current: $27.24
Upside: +10.13%
Initiates: Buy
Price Target: $21
Current: $11.67
Upside: +79.95%
Downgrades: Hold
Price Target: $21$25
Current: $10.28
Upside: +143.19%
Upgrades: Buy
Price Target: n/a
Current: $30.07
Upside: -